<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66392">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02241564</url>
  </required_header>
  <id_info>
    <org_study_id>MALTX-001</org_study_id>
    <nct_id>NCT02241564</nct_id>
  </id_info>
  <brief_title>Malignancies in Transplanted Patients</brief_title>
  <acronym>MALTX</acronym>
  <official_title>Follow-up of Malignancies in Transplanted Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to improve the overall treatment and outcome of renal, pancreas or
      liver transplanted patients who have encountered a malignancy by a structured treatment
      program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive
      treatment, follow-up and evaluation of the program.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient survival</measure>
    <time_frame>12 months, 2 years, 3 years</time_frame>
    <description>After inclusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>12 months, 2 years, 3 years</time_frame>
    <description>After inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ImmuKnow Assay value</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour progression/regression/reoccurrence</measure>
    <time_frame>12 months, 2 years, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintained switch of immunosuppression from calcineurin inhibitor to mTOR inhibitor</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>12 months, 2 years, 3 years</time_frame>
    <description>Creatinine measure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Malignancy post transplantation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection</intervention_name>
    <arm_group_label>Malignancy post transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch from calcineurin inhibitor to an mTOR inhibitor</intervention_name>
    <arm_group_label>Malignancy post transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney, pancreas or liver transplanted patients in the Uppsala/Örebro region with a
        diagnosed malignancy pre or post transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing and capable of giving written informed consent of participation in
             the project

          -  Patients with a previous diagnosed or presently diagnosed or reoccurrence of a
             malignancy (other then basal cell carcinoma)

        Exclusion Criteria:

          -  Patients with a primary liver cancer as cause of the transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vivan Hellström, MD</last_name>
    <phone>+46186110000</phone>
    <email>vivan.hellstrom@akademiska.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunnar Tufveson, MD, PhD</last_name>
    <phone>+46186110000</phone>
    <email>gunnar.tufveson@akademiska.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Surgery, Section of Transplantation Surgery, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivan Hellström, MD</last_name>
      <phone>+46186110000</phone>
      <email>vivan.hellstrom@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Gunnar Tufveson, MD, PhD</last_name>
      <phone>+46186110000</phone>
      <email>gunnar.tufveson@akademiska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Gunnar Tufveson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivan Hellström, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bengt von zur Mühlen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Hagberg, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gunilla Enblad, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>December 1, 2015</lastchanged_date>
  <firstreceived_date>September 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Tomas Lorant</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
